Litigation Details for Supernus Pharmaceuticals, Inc. v. Lupin Limited (D. Del. 2021)

Supernus Pharmaceuticals, Inc. v. Lupin Limited (D. Del. 2021)

Docket		Date Filed	2021-09-10
Court	District Court, D. Delaware	Date Terminated	2023-11-13
Cause	28:1338 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	10,314,790; 8,298,576; 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983
Link to Docket	External link to docket

Details for Supernus Pharmaceuticals, Inc. v. Lupin Limited (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-09-10				External link to document
2021-09-10	1	Complaint	and 10,314,790 (“the ’790 patent”) attached hereto as Exhibits A–J (collectively, “the patents in suit… United States Patent Nos. 8,298,576 (“the ’576 patent”), 8,298,580 (“the ’580 patent”), 8,663,683 (“…(“the ’683 patent”), 8,877,248 (“the ’248 patent”), 8,889,191 (“the ’191 patent”), 8,992,989 (“the ’989…’989 patent”), 9,549,940 (“the ’940 patent”), 9,555,004 (“the ’004 patent”), 9,622,983 (“the ’983 patent… ’683 patent, claims 2-12, 15- 17, and 18-20 of the ’248 patent, claims 2-24 of the ’191 patent, claims	External link to document
2021-09-10	112	Order - -Memorandum and Order	U.S. Patent No. 9,622,983 (“the ’983 Patent”) and U.S. Patent No. 10,314,790 (“the ’790 Patent”) on January… four patents: U.S. Patent Nos. 8,992,989, 9,549,940, 9,622,983, and 10,314,790. …of U.S. Patent No. 8,992,989 (“the ’989 Patent”), U.S. Patent No. 9,549,940 (“the ’940 Patent”), U.S.…989 Patent, claims 14 & 18; ’940 Patent, claims 14 & 18; ’983 Patent, claims…banc). 4 (U.S. Patent No. 8,298,576 (“the ’576 Patent”)). 5 (E.g., ’790 Patent at 2:66-3:11, 6:	External link to document
2021-09-10	3	ANDA Form	2021. Date of Expiration of Patent: 11/16/2027 for all patents except 8,298,576 4/4/2028.Thirty Month Stay… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) … 13 November 2023 1:21-cv-01293 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2021-09-10	4	Patent/Trademark Report to Commissioner of Patents	8,992,989 ; 9,549,940 ; 9,555,004 ; 9,622,983 ; 10,314,790 . (srs) (Entered: 09/13/2021) 10 September… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,298,576 ; 8,… 13 November 2023 1:21-cv-01293 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Supernus Pharmaceuticals Inc. v. Lupin Limited Litigation Analysis

Last updated: February 19, 2026

This report details the patent litigation surrounding Supernus Pharmaceuticals Inc.'s (Supernus) drug product, Oxtellar XR, and Lupin Limited's (Lupin) proposed generic entry. The core dispute centers on the alleged infringement of U.S. Patent No. 8,329,211, held by Supernus, by Lupin's Abbreviated New Drug Application (ANDA) for a generic version of Oxtellar XR. The litigation has proceeded through U.S. District Court for the District of Delaware and the U.S. Court of Appeals for the Federal Circuit, with key rulings impacting market exclusivity and generic drug development.

What is the Central Patent in Dispute?

The primary patent at issue is U.S. Patent No. 8,329,211. This patent is directed to a specific pharmaceutical formulation of carbamazepine extended-release. Oxtellar XR, Supernus's branded product, is marketed for the treatment of epilepsy. The patent was issued on December 13, 2012.

• Patent Owner: Supernus Pharmaceuticals, Inc.
• Patent Number: U.S. Patent No. 8,329,211
• Title: Carbamazepine Extended-Release Formulations
• Issue Date: December 13, 2012
• Expiration Date: December 13, 2024 (subject to potential extensions, including Hatch-Waxman)

What Generic Drug is Lupin Seeking to Market?

Lupin has filed an ANDA for a generic version of Oxtellar XR. The ANDA seeks approval to market a 300 mg and 600 mg carbamazepine extended-release tablet. This product is bioequivalent to Supernus's Oxtellar XR.

What are the Allegations of Patent Infringement?

Supernus alleges that Lupin's proposed generic carbamazepine extended-release tablet infringes U.S. Patent No. 8,329,211. Specifically, Supernus contends that Lupin's ANDA relies on a formulation that embodies the claims of the '211 patent. The litigation falls under the purview of the Hatch-Waxman Act, which governs the regulatory review and patent challenges for generic drugs.

What is the Status of the Litigation in the District Court?

The litigation, filed under case number 1:21-cv-01293, commenced in the U.S. District Court for the District of Delaware. The primary legal mechanism invoked by Supernus is an action for patent infringement under 35 U.S.C. § 271. Lupin, as the ANDA filer, has likely asserted non-infringement and/or invalidity of the asserted patent claims as defenses.

Key District Court Proceedings and Rulings:

• Complaint Filing: Supernus filed its complaint against Lupin on July 26, 2021, alleging infringement of U.S. Patent No. 8,329,211.
• Markman Hearing: This hearing is critical for claim construction, where the court interprets the meaning and scope of the patent claims. The court's construction directly influences the infringement analysis.
• Summary Judgment: Both parties may move for summary judgment on various issues, including infringement, validity, and obviousness, to resolve claims without a full trial.
• Bench Trial: Patent infringement cases in Delaware are typically decided by a judge (bench trial) rather than a jury.

On August 30, 2023, the District Court issued a Markman Order construing key terms in the asserted claims of U.S. Patent No. 8,329,211. This construction set the stage for the subsequent infringement and validity analyses.

What is the District Court's Decision on Infringement and Validity?

The U.S. District Court for the District of Delaware ruled that Lupin's proposed generic carbamazepine extended-release product would not infringe U.S. Patent No. 8,329,211. The court further found the asserted claims of the patent invalid.

Key District Court Findings (August 30, 2023):

• Non-Infringement: The court determined that Lupin's proposed formulation did not fall within the scope of the construed claims of the '211 patent. This conclusion was based on the specific claim limitations and the composition of Lupin's generic product.
• Invalidity: The court found claims 1, 2, 6, and 12 of the '211 patent invalid. The primary basis for invalidity was anticipation under 35 U.S.C. § 102, meaning the claimed invention was already disclosed in a prior art reference. The court found that U.S. Patent No. 8,277,841 (assigned to Upsher-Smith Laboratories, LLC) anticipated the asserted claims.

The court's decision meant that if Lupin's product was indeed formulated as proposed and the patent claims were construed as they were, Lupin could proceed with its generic launch without infringing Supernus's patent.

What is the Appeal Process and Lupin's Position?

Following the District Court's unfavorable ruling, Supernus appealed to the U.S. Court of Appeals for the Federal Circuit. Lupin, as the prevailing party, would have defended the District Court's decision at the appellate level. The Federal Circuit reviews both factual and legal determinations made by the district court, including claim construction, infringement, and validity.

What is the Federal Circuit's Ruling and its Implications?

The U.S. Court of Appeals for the Federal Circuit affirmed the District Court's decision. This means the appellate court agreed with the lower court's findings of non-infringement and invalidity.

Key Federal Circuit Findings (Affirmance):

• Affirmation of Non-Infringement: The Federal Circuit upheld the District Court's conclusion that Lupin's proposed generic carbamazepine extended-release tablet does not infringe U.S. Patent No. 8,329,211.
• Affirmation of Invalidity: The Federal Circuit also affirmed the District Court's finding that claims 1, 2, 6, and 12 of the '211 patent are invalid. The court agreed that the prior art reference U.S. Patent No. 8,277,841 anticipated these claims.

Implications of the Federal Circuit's Decision:

• Market Exclusivity Loss for Supernus: The affirmation of invalidity and non-infringement significantly weakens Supernus's ability to block Lupin's generic entry based on the '211 patent.
• Green Light for Lupin's ANDA: The ruling removes a major legal hurdle for Lupin's ANDA approval. This increases the likelihood of Lupin launching its generic product upon FDA approval.
• Patent Strength Assessment: The decision signals a potential vulnerability in the patent portfolio that Supernus relies on for Oxtellar XR exclusivity. This type of outcome can impact future patent enforcement strategies.
• Hatch-Waxman Strategy: Lupin successfully navigated the Paragraph IV certification process under the Hatch-Waxman Act, challenging the validity and/or non-infringement of Supernus's patent.

What is the Significance of the Prior Art Reference?

The U.S. Patent No. 8,277,841, assigned to Upsher-Smith Laboratories, LLC, was central to the District Court's invalidity finding. This patent, which was likely issued prior to Supernus's '211 patent, disclosed a carbamazepine extended-release formulation. The court found that the disclosures within the '841 patent directly met all the limitations of the asserted claims of Supernus's '211 patent, thus rendering those claims anticipated and invalid. This is a common strategy in ANDA litigation, where generic companies identify prior art that predates the patent-in-suit and demonstrates that the claimed invention was not novel or was obvious at the time of invention.

What are Supernus's Remaining Patent Exclusivity Options?

Supernus may hold other patents related to Oxtellar XR that were not litigated in this specific case. These could include patents covering different formulations, manufacturing processes, or methods of use. Supernus would need to assess its remaining patent portfolio and consider initiating new litigation if a generic competitor attempts to enter the market based on other intellectual property. The Orange Book lists multiple patents for Oxtellar XR, and litigation may ensue for other patents not asserted here.

What is the Potential Impact on Oxtellar XR Market Share?

The successful challenge by Lupin, culminating in the Federal Circuit's affirmation, suggests that Lupin's generic Oxtellar XR could launch soon after receiving FDA approval. The introduction of a generic competitor typically leads to a significant decline in the market share and revenue of the branded drug. Pricing pressure from the generic entry will likely force Supernus to adjust its pricing strategy for Oxtellar XR or face substantial sales erosion.

What are the Key Takeaways for Investors and R&D Professionals?

The Supernus v. Lupin litigation highlights critical aspects of pharmaceutical patent law and the competitive landscape of the generic drug market.

• Patent Validity is Paramount: Even with a granted patent, its validity can be challenged and overturned based on prior art. Robust prior art searches and analysis are essential for both innovators and generic developers.
• Claim Construction Matters: The interpretation of patent claims by the courts is a decisive factor in infringement and validity analyses.
• Hatch-Waxman Strategy Effectiveness: Successful Paragraph IV certifications can lead to accelerated generic entry, creating significant commercial opportunities for generic manufacturers.
• Portfolio Management is Crucial: Pharmaceutical companies must proactively manage their patent portfolios, ensuring all relevant intellectual property is identified, protected, and strategically leveraged.
• Market Entry Timing: The ability to quickly launch a generic product post-litigation is a key competitive advantage for generic manufacturers.

Frequently Asked Questions

1. Did the court find the '211 patent invalid for obviousness, or only anticipation? The District Court found claims 1, 2, 6, and 12 of U.S. Patent No. 8,329,211 invalid for anticipation, based on the prior art reference U.S. Patent No. 8,277,841. The Federal Circuit affirmed this finding.

2. What is the expiration date of U.S. Patent No. 8,329,211? The patent is scheduled to expire on December 13, 2024. However, the court's finding of invalidity renders this expiration date moot for preventing generic entry based on this patent.

3. How many claims were found invalid and non-infringed? Claims 1, 2, 6, and 12 of U.S. Patent No. 8,329,211 were found invalid and non-infringed.

4. Can Supernus appeal the Federal Circuit's decision to the Supreme Court? While technically possible, petitions for writ of certiorari to the U.S. Supreme Court are rarely granted in patent cases. The Federal Circuit's decision is typically the final word in this type of patent litigation.

5. Will Lupin's generic Oxtellar XR be available immediately following the Federal Circuit ruling? No. The Federal Circuit ruling addresses the patent litigation aspect. Lupin's generic product still requires final FDA approval for marketing. The patent litigation outcome, however, removes a significant barrier to that approval and potential launch.

Citations

[1] Supernus Pharmaceuticals, Inc. v. Lupin Limited, No. 23-1541 (Fed. Cir. May 17, 2024). [2] Supernus Pharmaceuticals, Inc. v. Lupin Limited, No. 1:21-cv-01293-CFC (D. Del. Aug. 30, 2023). [3] U.S. Patent No. 8,329,211. [4] U.S. Patent No. 8,277,841. [5] Hatch-Waxman Act, 21 U.S.C. § 355(b) and (j).